Osivax and GC Biopharma revealed a new alliance aimed at developing a more advanced influenza vaccine. The vaccine aims to combine OVX836 and GC FLU. Osivax secured rights to pursue a combined shot.
Older adults are facing four vaccine decisions this fall, while the federal immunization calendar continues to carry a 2025 date. Flu and pneumonia deaths have dropped for 25 years, but one American age group posted an uptick.